Supplementary Table S1 from Randomized Phase II Cabazitaxel Dose Individualization and Neutropenia Prevention Trial in Patients with Metastatic Castration-Resistant Prostate Cancer Article Swipe
Aurelius Omlin
,
Richard Cathomas
,
Gunhild von Amsberg
,
Christoph Reuter
,
Susan Feyerabend
,
Wolfgang Loidl
,
Martin Boegemann
,
Anja Lorch
,
Axel Heidenreich
,
Igor Tsaur
,
Julian Larcher‐Senn
,
Stefan A.J. Buck
,
Ron H.J. Mathijssen
,
Ulrich Jaehde
,
Silke Gillessen
,
Markus Joerger
·
YOU?
·
· 2023
· Open Access
·
· DOI: https://doi.org/10.1158/1078-0432.22553394
YOU?
·
· 2023
· Open Access
·
· DOI: https://doi.org/10.1158/1078-0432.22553394
Representativeness of Study Participants
Related Topics
Concepts
Cabazitaxel
Prostate cancer
Medicine
Neutropenia
Oncology
Randomized controlled trial
Internal medicine
Cancer
Chemotherapy
Androgen deprivation therapy
Metadata
- Type
- supplementary-materials
- Language
- en
- Landing Page
- https://doi.org/10.1158/1078-0432.22553394
- OA Status
- gold
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4362541583
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4362541583Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1158/1078-0432.22553394Digital Object Identifier
- Title
-
Supplementary Table S1 from Randomized Phase II Cabazitaxel Dose Individualization and Neutropenia Prevention Trial in Patients with Metastatic Castration-Resistant Prostate CancerWork title
- Type
-
supplementary-materialsOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2023Year of publication
- Publication date
-
2023-04-04Full publication date if available
- Authors
-
Aurelius Omlin, Richard Cathomas, Gunhild von Amsberg, Christoph Reuter, Susan Feyerabend, Wolfgang Loidl, Martin Boegemann, Anja Lorch, Axel Heidenreich, Igor Tsaur, Julian Larcher‐Senn, Stefan A.J. Buck, Ron H.J. Mathijssen, Ulrich Jaehde, Silke Gillessen, Markus JoergerList of authors in order
- Landing page
-
https://doi.org/10.1158/1078-0432.22553394Publisher landing page
- Open access
-
YesWhether a free full text is available
- OA status
-
goldOpen access status per OpenAlex
- OA URL
-
https://doi.org/10.1158/1078-0432.22553394Direct OA link when available
- Concepts
-
Cabazitaxel, Prostate cancer, Medicine, Neutropenia, Oncology, Randomized controlled trial, Internal medicine, Cancer, Chemotherapy, Androgen deprivation therapyTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
0Total citation count in OpenAlex
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W4362541583 |
|---|---|
| doi | https://doi.org/10.1158/1078-0432.22553394 |
| ids.doi | https://doi.org/10.1158/1078-0432.22553394 |
| ids.openalex | https://openalex.org/W4362541583 |
| fwci | |
| type | supplementary-materials |
| title | Supplementary Table S1 from Randomized Phase II Cabazitaxel Dose Individualization and Neutropenia Prevention Trial in Patients with Metastatic Castration-Resistant Prostate Cancer |
| biblio.issue | |
| biblio.volume | |
| biblio.last_page | |
| biblio.first_page | |
| topics[0].id | https://openalex.org/T10543 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 0.9991999864578247 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2740 |
| topics[0].subfield.display_name | Pulmonary and Respiratory Medicine |
| topics[0].display_name | Prostate Cancer Treatment and Research |
| topics[1].id | https://openalex.org/T11914 |
| topics[1].field.id | https://openalex.org/fields/27 |
| topics[1].field.display_name | Medicine |
| topics[1].score | 0.9977999925613403 |
| topics[1].domain.id | https://openalex.org/domains/4 |
| topics[1].domain.display_name | Health Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2730 |
| topics[1].subfield.display_name | Oncology |
| topics[1].display_name | PARP inhibition in cancer therapy |
| topics[2].id | https://openalex.org/T11752 |
| topics[2].field.id | https://openalex.org/fields/27 |
| topics[2].field.display_name | Medicine |
| topics[2].score | 0.9894999861717224 |
| topics[2].domain.id | https://openalex.org/domains/4 |
| topics[2].domain.display_name | Health Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2730 |
| topics[2].subfield.display_name | Oncology |
| topics[2].display_name | Cancer Treatment and Pharmacology |
| is_xpac | False |
| apc_list | |
| apc_paid | |
| concepts[0].id | https://openalex.org/C2778971682 |
| concepts[0].level | 5 |
| concepts[0].score | 0.9632381796836853 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q412963 |
| concepts[0].display_name | Cabazitaxel |
| concepts[1].id | https://openalex.org/C2780192828 |
| concepts[1].level | 3 |
| concepts[1].score | 0.7805885076522827 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q181257 |
| concepts[1].display_name | Prostate cancer |
| concepts[2].id | https://openalex.org/C71924100 |
| concepts[2].level | 0 |
| concepts[2].score | 0.7351362705230713 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[2].display_name | Medicine |
| concepts[3].id | https://openalex.org/C2777063308 |
| concepts[3].level | 3 |
| concepts[3].score | 0.697901725769043 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q1435822 |
| concepts[3].display_name | Neutropenia |
| concepts[4].id | https://openalex.org/C143998085 |
| concepts[4].level | 1 |
| concepts[4].score | 0.630317211151123 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q162555 |
| concepts[4].display_name | Oncology |
| concepts[5].id | https://openalex.org/C168563851 |
| concepts[5].level | 2 |
| concepts[5].score | 0.5263123512268066 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q1436668 |
| concepts[5].display_name | Randomized controlled trial |
| concepts[6].id | https://openalex.org/C126322002 |
| concepts[6].level | 1 |
| concepts[6].score | 0.5195746421813965 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[6].display_name | Internal medicine |
| concepts[7].id | https://openalex.org/C121608353 |
| concepts[7].level | 2 |
| concepts[7].score | 0.318840891122818 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q12078 |
| concepts[7].display_name | Cancer |
| concepts[8].id | https://openalex.org/C2776694085 |
| concepts[8].level | 2 |
| concepts[8].score | 0.14745396375656128 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q974135 |
| concepts[8].display_name | Chemotherapy |
| concepts[9].id | https://openalex.org/C2777899217 |
| concepts[9].level | 4 |
| concepts[9].score | 0.06704950332641602 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q4759439 |
| concepts[9].display_name | Androgen deprivation therapy |
| keywords[0].id | https://openalex.org/keywords/cabazitaxel |
| keywords[0].score | 0.9632381796836853 |
| keywords[0].display_name | Cabazitaxel |
| keywords[1].id | https://openalex.org/keywords/prostate-cancer |
| keywords[1].score | 0.7805885076522827 |
| keywords[1].display_name | Prostate cancer |
| keywords[2].id | https://openalex.org/keywords/medicine |
| keywords[2].score | 0.7351362705230713 |
| keywords[2].display_name | Medicine |
| keywords[3].id | https://openalex.org/keywords/neutropenia |
| keywords[3].score | 0.697901725769043 |
| keywords[3].display_name | Neutropenia |
| keywords[4].id | https://openalex.org/keywords/oncology |
| keywords[4].score | 0.630317211151123 |
| keywords[4].display_name | Oncology |
| keywords[5].id | https://openalex.org/keywords/randomized-controlled-trial |
| keywords[5].score | 0.5263123512268066 |
| keywords[5].display_name | Randomized controlled trial |
| keywords[6].id | https://openalex.org/keywords/internal-medicine |
| keywords[6].score | 0.5195746421813965 |
| keywords[6].display_name | Internal medicine |
| keywords[7].id | https://openalex.org/keywords/cancer |
| keywords[7].score | 0.318840891122818 |
| keywords[7].display_name | Cancer |
| keywords[8].id | https://openalex.org/keywords/chemotherapy |
| keywords[8].score | 0.14745396375656128 |
| keywords[8].display_name | Chemotherapy |
| keywords[9].id | https://openalex.org/keywords/androgen-deprivation-therapy |
| keywords[9].score | 0.06704950332641602 |
| keywords[9].display_name | Androgen deprivation therapy |
| language | en |
| locations[0].id | doi:10.1158/1078-0432.22553394 |
| locations[0].is_oa | True |
| locations[0].source | |
| locations[0].license | cc-by |
| locations[0].pdf_url | |
| locations[0].version | acceptedVersion |
| locations[0].raw_type | posted-content |
| locations[0].license_id | https://openalex.org/licenses/cc-by |
| locations[0].is_accepted | True |
| locations[0].is_published | False |
| locations[0].raw_source_name | |
| locations[0].landing_page_url | https://doi.org/10.1158/1078-0432.22553394 |
| indexed_in | crossref |
| authorships[0].author.id | https://openalex.org/A5041581270 |
| authorships[0].author.orcid | https://orcid.org/0000-0002-4783-4788 |
| authorships[0].author.display_name | Aurelius Omlin |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Aurelius Omlin |
| authorships[0].is_corresponding | False |
| authorships[1].author.id | https://openalex.org/A5050931392 |
| authorships[1].author.orcid | https://orcid.org/0000-0002-9677-9885 |
| authorships[1].author.display_name | Richard Cathomas |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Richard Cathomas |
| authorships[1].is_corresponding | False |
| authorships[2].author.id | https://openalex.org/A5038268175 |
| authorships[2].author.orcid | https://orcid.org/0000-0002-5176-0507 |
| authorships[2].author.display_name | Gunhild von Amsberg |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Gunhild von Amsberg |
| authorships[2].is_corresponding | False |
| authorships[3].author.id | https://openalex.org/A5023951689 |
| authorships[3].author.orcid | https://orcid.org/0000-0001-9041-4669 |
| authorships[3].author.display_name | Christoph Reuter |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Christoph Reuter |
| authorships[3].is_corresponding | False |
| authorships[4].author.id | https://openalex.org/A5005992335 |
| authorships[4].author.orcid | https://orcid.org/0000-0002-2261-4228 |
| authorships[4].author.display_name | Susan Feyerabend |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Susan Feyerabend |
| authorships[4].is_corresponding | False |
| authorships[5].author.id | https://openalex.org/A5079977409 |
| authorships[5].author.orcid | https://orcid.org/0000-0001-9354-5728 |
| authorships[5].author.display_name | Wolfgang Loidl |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | Wolfgang Loidl |
| authorships[5].is_corresponding | False |
| authorships[6].author.id | https://openalex.org/A5108724134 |
| authorships[6].author.orcid | |
| authorships[6].author.display_name | Martin Boegemann |
| authorships[6].author_position | middle |
| authorships[6].raw_author_name | Martin Boegemann |
| authorships[6].is_corresponding | False |
| authorships[7].author.id | https://openalex.org/A5042221345 |
| authorships[7].author.orcid | https://orcid.org/0000-0003-1681-3287 |
| authorships[7].author.display_name | Anja Lorch |
| authorships[7].author_position | middle |
| authorships[7].raw_author_name | Anja Lorch |
| authorships[7].is_corresponding | False |
| authorships[8].author.id | https://openalex.org/A5048118430 |
| authorships[8].author.orcid | https://orcid.org/0000-0002-2511-3664 |
| authorships[8].author.display_name | Axel Heidenreich |
| authorships[8].author_position | middle |
| authorships[8].raw_author_name | Axel Heidenreich |
| authorships[8].is_corresponding | False |
| authorships[9].author.id | https://openalex.org/A5002485183 |
| authorships[9].author.orcid | https://orcid.org/0000-0001-5107-3523 |
| authorships[9].author.display_name | Igor Tsaur |
| authorships[9].author_position | middle |
| authorships[9].raw_author_name | Igor Tsaur |
| authorships[9].is_corresponding | False |
| authorships[10].author.id | https://openalex.org/A5090323339 |
| authorships[10].author.orcid | https://orcid.org/0000-0003-3169-1900 |
| authorships[10].author.display_name | Julian Larcher‐Senn |
| authorships[10].author_position | middle |
| authorships[10].raw_author_name | Julian Larcher-Senn |
| authorships[10].is_corresponding | False |
| authorships[11].author.id | https://openalex.org/A5003898949 |
| authorships[11].author.orcid | https://orcid.org/0000-0003-1367-8403 |
| authorships[11].author.display_name | Stefan A.J. Buck |
| authorships[11].author_position | middle |
| authorships[11].raw_author_name | Stefan A.J. Buck |
| authorships[11].is_corresponding | False |
| authorships[12].author.id | https://openalex.org/A5074174053 |
| authorships[12].author.orcid | https://orcid.org/0000-0001-5667-5697 |
| authorships[12].author.display_name | Ron H.J. Mathijssen |
| authorships[12].author_position | middle |
| authorships[12].raw_author_name | Ron H.J. Mathijssen |
| authorships[12].is_corresponding | False |
| authorships[13].author.id | https://openalex.org/A5082379986 |
| authorships[13].author.orcid | https://orcid.org/0000-0002-2493-7370 |
| authorships[13].author.display_name | Ulrich Jaehde |
| authorships[13].author_position | middle |
| authorships[13].raw_author_name | Ulrich Jaehde |
| authorships[13].is_corresponding | False |
| authorships[14].author.id | https://openalex.org/A5009101766 |
| authorships[14].author.orcid | https://orcid.org/0000-0001-5746-6555 |
| authorships[14].author.display_name | Silke Gillessen |
| authorships[14].author_position | middle |
| authorships[14].raw_author_name | Silke Gillessen |
| authorships[14].is_corresponding | False |
| authorships[15].author.id | https://openalex.org/A5022167252 |
| authorships[15].author.orcid | https://orcid.org/0000-0001-6602-6287 |
| authorships[15].author.display_name | Markus Joerger |
| authorships[15].author_position | last |
| authorships[15].raw_author_name | Markus Joerger |
| authorships[15].is_corresponding | False |
| has_content.pdf | False |
| has_content.grobid_xml | False |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://doi.org/10.1158/1078-0432.22553394 |
| open_access.oa_status | gold |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | Supplementary Table S1 from Randomized Phase II Cabazitaxel Dose Individualization and Neutropenia Prevention Trial in Patients with Metastatic Castration-Resistant Prostate Cancer |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T10543 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 0.9991999864578247 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2740 |
| primary_topic.subfield.display_name | Pulmonary and Respiratory Medicine |
| primary_topic.display_name | Prostate Cancer Treatment and Research |
| related_works | https://openalex.org/W2948591392, https://openalex.org/W2072623499, https://openalex.org/W4224880568, https://openalex.org/W2134403636, https://openalex.org/W3191817735, https://openalex.org/W1985873333, https://openalex.org/W2898496072, https://openalex.org/W1881444711, https://openalex.org/W2924397895, https://openalex.org/W4382062226 |
| cited_by_count | 0 |
| locations_count | 1 |
| best_oa_location.id | doi:10.1158/1078-0432.22553394 |
| best_oa_location.is_oa | True |
| best_oa_location.source | |
| best_oa_location.license | cc-by |
| best_oa_location.pdf_url | |
| best_oa_location.version | acceptedVersion |
| best_oa_location.raw_type | posted-content |
| best_oa_location.license_id | https://openalex.org/licenses/cc-by |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | False |
| best_oa_location.raw_source_name | |
| best_oa_location.landing_page_url | https://doi.org/10.1158/1078-0432.22553394 |
| primary_location.id | doi:10.1158/1078-0432.22553394 |
| primary_location.is_oa | True |
| primary_location.source | |
| primary_location.license | cc-by |
| primary_location.pdf_url | |
| primary_location.version | acceptedVersion |
| primary_location.raw_type | posted-content |
| primary_location.license_id | https://openalex.org/licenses/cc-by |
| primary_location.is_accepted | True |
| primary_location.is_published | False |
| primary_location.raw_source_name | |
| primary_location.landing_page_url | https://doi.org/10.1158/1078-0432.22553394 |
| publication_date | 2023-04-04 |
| publication_year | 2023 |
| referenced_works_count | 0 |
| abstract_inverted_index.of | 1 |
| abstract_inverted_index.Study | 2 |
| abstract_inverted_index.Participants</p> | 3 |
| abstract_inverted_index.<p>Representativeness | 0 |
| cited_by_percentile_year | |
| countries_distinct_count | 0 |
| institutions_distinct_count | 16 |
| citation_normalized_percentile.value | 0.18569201 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |